The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Platinum chemotherapy utilization declined by 15.1% at the height of the national shortage. The shortage did not translate to an increase in short-term mortality. The shortage of generic ...

The oncometabolite D-2-HG has been implicated in compromising DNA repair pathway. Here the authors show D-2-HG leads to genome-wide DNA hypermethylation and loss of CTCF coverage, which impairs ...

The protocol will enable new enrollment expressly focusing on patients with advanced, recurrent, platinum-resistant disease, a group that has shown durable clinical benefit from stenoparib in the ...

Human immunoconjugate molecule (hI-con1 ... Our group has recently evaluated the activity of hI-con1 against primary chemotherapy-resistant USC. Immunohistochemical analysis demonstrated TF ...

George Coukos, MD, PhD, Department of Oncology, University Hospital of Lausanne, Rue du Bugnon 46, Lausanne 1011, Switzerland; e-mail: [email protected]. If you have the appropriate software installed ...

USC is resistant to cytotoxic chemotherapy and is responsible for most recurrences and deaths from endometrial cancer. USC has a unique gene expression profile. Molecular markers can aid in ...